|25.09||+0.3700||+1.50%||Vol 403.34K||1Y Perf 28.22%|
|Aug 16th, 2022 16:00 DELAYED|
|- -||-0.71 -2.83%|
|Target Price||53.17||Analyst Rating||Strong Buy 1.10|
|Potential %||111.92||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||91.71||Earnings Rating||—|
|Market Cap||1.51B||Earnings Date||4th Aug 2022|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-1.38|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||474.09K|
|Avg. Monthly Volume||776.67K|
|Avg. Quarterly Volume||561.21K|
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) stock closed at 25.09 per share at the end of the most recent trading day (a 1.5% change compared to the prior day closing price) with a volume of 403.34K shares and market capitalization of 1.51B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 54 people. Arcutis Biotherapeutics Inc. CEO is Todd Franklin Watanabe.
The one-year performance of Arcutis Biotherapeutics Inc. stock is 28.22%, while year-to-date (YTD) performance is 20.97%. ARQT stock has a five-year performance of %. Its 52-week range is between 13.59 and 26.13, which gives ARQT stock a 52-week price range ratio of 91.71%
Arcutis Biotherapeutics Inc. currently has a PE ratio of -4.90, a price-to-book (PB) ratio of 7.74, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -70.92%, a ROC of -75.03% and a ROE of -85.28%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Arcutis Biotherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.38 for the next earnings report. Arcutis Biotherapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Arcutis Biotherapeutics Inc. is Strong Buy (1.1), with a target price of $53.17, which is +111.92% compared to the current price. The earnings rating for Arcutis Biotherapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arcutis Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arcutis Biotherapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.35, ATR14 : 1.64, CCI20 : 70.23, Chaikin Money Flow : -0.12, MACD : 0.71, Money Flow Index : 69.70, ROC : 5.82, RSI : 46.71, STOCH (14,3) : 84.21, STOCH RSI : 0.00, UO : 52.93, Williams %R : -15.79), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arcutis Biotherapeutics Inc. in the last 12-months were: David W. Osborne (Sold 6 025 shares of value $128 886 ), Howard G. Welgus (Option Excercise at a value of $24 701), Howard G. Welgus (Sold 33 500 shares of value $720 823 ), Kenneth Lock (Sold 1 958 shares of value $33 833 ), Patricia A. Turney (Option Excercise at a value of $265 097), Patricia A. Turney (Sold 1 959 shares of value $33 851 ), Patrick Burnett (Sold 1 011 shares of value $17 032 ), Scott L. Burrows (Sold 13 283 shares of value $264 700 ), Todd Franklin Watanabe (Option Excercise at a value of $30 733), Todd Franklin Watanabe (Sold 33 412 shares of value $764 998 )
Fri, 29 Jul 2022 17:55 GMT Mizuho Securities Believes Arcutis Biotherapeutics (ARQT) Still Has Room to Grow- TipRanks. All rights reserved.
Sun, 10 Jul 2022 23:55 GMT Mizuho Securities Believes Arcutis Biotherapeutics (ARQT) Wont Stop Here- TipRanks. All rights reserved.
Tue, 24 May 2022 15:56 GMT Arcutis Biotherapeutics (ARQT) Gets a Buy Rating from Mizuho Securities- TipRanks. All rights reserved.
Tue, 22 Mar 2022 23:05 GMT Arcutis Biotherapeutics (ARQT) Received its Third Buy in a Row- TipRanks. All rights reserved.
Tue, 18 Jan 2022 09:25 GMT Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.